

Ref. No:	1729
Date:	07/05/25
Subject:	Biologics Rheumatology

REQUEST & RESPONSE

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] 111
- Adalimumab [Humira] 48
- Adalimumab Biosimilars 422
- Apremilast [Otezla] 71
- Baricitinib [Olumiant] 12
- Bimekizumab [Bimzelx] 5
- Certolizumab [Cimzia] 35
- Etanercept [Enbrel] 39
- Etanercept Biosimilars 227
- Filgotinib [Jyseleca] 16
- Golimumab [Simponi] 47
- Guselkumab [Tremfya] 9
- Infliximab [Remicade] 0
- Infliximab Biosimilars 29
- Ixekizumab [Taltz] 7
- Risankizumab [Skyrizi] 0
- Rituximab [MabThera] 0
- Rituximab Biosimilars 24
- Sarilumab [Kevzara] 1
- Secukinumab [Cosentyx] 68
- Tocilizumab [Ro Actemra] 53
- Tocilizumab Biosimilars 31
- Tofacitinib [Xeljanz] 30
- Upadacitinib [Rinvoq] 23
- Ustekinumab [Stelara] 3
- Ustekinumab Biosimilar 11

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis (axSpA) ONLY in the last 3 months with the following drugs.

- Adalimumab [Humira] 0
- Adalimumab Biosimilars 2
- Bimekizumab [Bimzelx] 0
- Certolizumab [Cimzia] 1
- Etanercept [Enbrel] 0
- Etanercept Biosimilars 0
- Golimumab [Simponi] 0
- Infliximab [Remicade] 0
- Infliximab Biosimilars 0
- Ixekizumab [Taltz] 0
- Secukinumab [Cosentyx] 0
- Tofacitinib [Xeljanz] 0
- Upadacitinib [Rinvoq] 1